Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Immunotherapy Drugs Market 2016 Share, Trend, Segmentation and Forecast to 2022

Friday, October 7, 2016 5:12
% of readers think this story is Fact. Add your two cents.

(Before It's News)

According to researcher, the Global Immunotherapy Drugs market is accounted for $38.26 billion in 2015 and is expected to reach $97.47 billion by 2022 growing at a CAGR of 14.3%. In present scenario people are exposed to various harmful conditions which are affecting them through cancer and immunotherapy drugs are helping the people out. Rising cancer therapies coupled with lesser side effects are the factors provoking the market demand. Moreover high prevalence of lifestyle diseases are sustaining the market growth. However, high cost of therapy drugs is major factor restraining the market.

Monoclonal antibodies is accounted for largest market share while Checkpoint inhibitors is estimated to be the fastest growing segment on account of its less effect to normal cells compared to ordinary therapeutics. North America commanded the largest market share followed by Europe owing to large government funding in cancer techniques and R&D. Quick drug approvals is also a major factor helping the regional growth.

Request a sample report @

Some of the key players of the Immunotherapy Drugs market include Aduro BioTech Inc, Agenus Inc, Amgen Inc., Bavarian Nordic A/S, Bellicum Pharmaceuticals Inc, Biogen Idec Inc, Bristol-Myers Squibb Company, Celgene Corporation, DenDrit Biotech USA, ELI Lilly and Company, F. Hoffmann-La Roche Ag, Galena Biopharma Inc, Genentech Inc, Glaxosmithkline Plc, Merck & Co., Inc., NewLink Genetics Corp., Novartis International Ag, Oxford BioTherapeutics Ltd., Seattle Genetics, Inc. and Spectrum Pharmaceuticals, Inc.. 

Drug Types Covered: 
• Checkpoint Inhibitors 
• Interferons 
• Interleukins 
• Monoclonal Antibodies 
• Vaccines

Applications Covered: 
• Blood Cancer 
• Breast Cancer 
• Cervical Cancer 
• Gastric Cancer 
• Glioblastoma 
• Lung Cancer 
• Melanoma 
• Prostate Cancer

What our report offers: 
- Market share assessments for the regional and country level segments 
- Market share analysis of the top industry players 
- Strategic recommendations for the new entrants 
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets 
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) 
- Strategic recommendations in key business segments based on the market estimations 
- Competitive landscaping mapping the key common trends 
- Company profiling with detailed strategies, financials, and recent developments 
- Supply chain trends mapping the latest technological advancements

Get this report @

Key points in table of content

1 Executive Summary 

2 Preface 
2.1 Abstract 
2.2 Stake Holders 
2.3 Research Scope 
2.4 Research Methodology 
2.4.1 Data Mining 
2.4.2 Data Analysis 
2.4.3 Data Validation 
2.4.4 Research Approach 
2.5 Research Sources 
2.5.1 Primary Research Sources 
2.5.2 Secondary Research Sources 
2.5.3 Assumptions 

3 Market Trend Analysis 
3.1 Introduction 
3.2 Drivers 
3.3 Restraints 
3.4 Opportunities 
3.5 Threats 
3.6 Product Analysis 
3.7 Application Analysis 
3.8 Emerging markets 

4 Porters Five Force Analysis 
4.1 Bargaining power of suppliers 
4.2 Bargaining power of buyers 
4.3 Threat of substitutes 
4.4 Threat of new entrants 
4.5 Competitive rivalry 

5 Global Immunotherapy Drugs, By Type of Drugs 
5.1 Introduction 
5.2 Checkpoint Inhibitors 
5.3 Interferons 
5.4 Interleukins 
5.5 Monoclonal Antibodies 
5.6 Vaccines 

6 Global Immunotherapy Drugs, By Application 
6.1 Introduction 
6.2 Blood Cancer 
6.3 Breast Cancer 
6.4 Cervical Cancer 
6.5 Gastric Cancer 
6.6 Glioblastoma 
6.7 Lung Cancer 
6.8 Melanoma 
6.9 Prostate Cancer 

7 Global Immunotherapy Drugs market, By Geography 
7.1 North America 
7.1.1 US 
7.1.2 Canada 
7.1.3 Mexico 
7.2 Europe 
7.2.1 Germany 
7.2.2 France 
7.2.3 Italy 
7.2.4 UK 
7.2.5 Spain 
7.2.6 Rest of Europe 
7.3 Asia Pacific 
7.3.1 Japan 
7.3.2 China 
7.3.3 India 
7.3.4 Australia 
7.3.5 New Zealand 
7.3.6 Rest of Asia Pacific 
7.4 Rest of the World 
7.4.1 Middle East 
7.4.2 Brazil 
7.4.3 Argentina 
7.4.4 South Africa 
7.4.5 Egypt 

8 Key Developments 
8.1 Agreements, Partnerships, Collaborations and Joint Ventures 
8.2 Acquisitions & Mergers 
8.3 New Product Launch 
8.4 Expansions 
8.5 Other Key Strategies 

9 Company Profiling 
9.1 Aduro BioTech Inc 
9.2 Agenus Inc 
9.3 Amgen Inc. 
9.4 Bavarian Nordic A/S 
9.5 Bellicum Pharmaceuticals Inc 
9.6 Biogen Idec Inc 
9.7 Bristol-Myers Squibb Company 
9.8 Celgene Corporation 
9.9 DenDrit Biotech USA 
9.10 ELI Lilly and Company 
9.11 F. Hoffmann-La Roche Ag 
9.12 Galena Biopharma Inc 
9.13 Genentech Inc 
9.14 Glaxosmithkline Plc 
9.15 Merck & Co., Inc. 
9.16 NewLink Genetics Corp. 
9.17 Novartis International Ag 
9.18 Oxford BioTherapeutics Ltd. 
9.19 Seattle Genetics, Inc. 
9.20 Spectrum Pharmaceuticals, Inc        

Complete report details @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.